Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors.
EGFR
NSCLC
Prognostic factor
TP53
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
13
01
2023
revised:
24
01
2023
accepted:
24
01
2023
medline:
3
4
2023
pubmed:
12
2
2023
entrez:
11
2
2023
Statut:
ppublish
Résumé
To assess the prognostic impact of TP53 mutations in EGFR-mutant advanced NSCLC patients treated with TKIs. Studies exploring the clinical outcomes of EGFR mutant/TP53 wild-type versus EGFR/TP53 co-mutant patients treated with TKIs were selected. Data were cumulated by adopting a fixed and random-effect model. Overall, 29 trials were eligible. The PFS analysis showed that TP53 co-mutant group has shorter PFS versus EGFR mutant/TP53 wild-type group (HR = 1.67, 95% CI 1.51-1.83, heterogeneity I TP53 mutations represent a clinically relevant mechanism of resistance to EGFR-TKIs, regardless of their generation. A personalized therapeutical approach should be explored in dedicated clinical trials.
Identifiants
pubmed: 36773668
pii: S1040-8428(23)00017-3
doi: 10.1016/j.critrevonc.2023.103929
pii:
doi:
Substances chimiques
Tyrosine Kinase Inhibitors
0
ErbB Receptors
EC 2.7.10.1
Protein Kinase Inhibitors
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
EGFR protein, human
EC 2.7.10.1
Types de publication
Meta-Analysis
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103929Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.